IHH Healthcare Stock

Equities

IHH

MYL5225OO007

Healthcare Facilities & Services

End-of-day quote BURSA MALAYSIA 06:00:00 2024-05-23 pm EDT 5-day change 1st Jan Change
6.27 MYR +0.32% Intraday chart for IHH Healthcare 0.00% +3.98%
Sales 2024 * 22.06B 4.68B Sales 2025 * 23.58B 5.01B Capitalization 55.22B 11.73B
Net income 2024 * 1.73B 367M Net income 2025 * 1.92B 407M EV / Sales 2024 * 2.81 x
Net Debt 2024 * 6.85B 1.46B Net Debt 2025 * 6.5B 1.38B EV / Sales 2025 * 2.62 x
P/E ratio 2024 *
31.5 x
P/E ratio 2025 *
28.8 x
Employees 65,000
Yield 2024 *
1.27%
Yield 2025 *
1.37%
Free-Float 24.15%
More Fundamentals * Assessed data
Dynamic Chart
IHH Healthcare Berhad Announces Retirement of Miss Ong Ai Lin as Independent and Non Executive Member of Risk Committee CI
IHH Healthcare Berhad Announces Retirement of Ong Ai Lin as Independent and Non Executive Member of Nomination and Remuneration Committee, Effective May 28, 2024 CI
IHH Healthcare Berhad Announces Retirement of Tan Sri Mohammed Azlan Bin Hashim as Chairman Independent and Non Executive, Effective May 28, 2024 CI
IHH Healthcare Berhad Announces Retirement of Ong Ai Lin as Independent and Non Executive Director, Effective May 28, 2024 CI
IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court MT
Belun Technology announced that it has received funding from IHH Healthcare Berhad CI
IHH Healthcare Names CFO MT
IHH Healthcare Berhad Appoints Dilip Kadambi as Group Chief Financial Officer CI
Ihh Healthcare Berhad Announces Resignation of Takeshi Akutsu as Non Independent and Non Executive Director, Effective March 31, 2024 CI
Ihh Healthcare Berhad Appoints Yoichiro Endo as Non Independent and Non Executive Director CI
Ihh Healthcare Berhad Announces Resignation of Takeshi Akutsu as Non Independent and Non Executive Member of Nomination and Remuneration Committee CI
Ihh Healthcare Berhad Appoints Yoichiro Endo as Non Independent and Non Executive Member of Nomination and Remuneration Committee CI
IHH Healthcare Seeks Shareholder Approval for Buyback Program MT
IHH Healthcare Issues New Shares Pursuant to Exercise of Options MT
Transcript : IHH Healthcare Berhad, Q4 2023 Earnings Call, Mar 01, 2024
More news
1 day+0.32%
Current month-0.95%
3 months+1.29%
6 months+8.10%
Current year+3.98%
More quotes
1 week
6.20
Extreme 6.2
6.34
1 month
6.18
Extreme 6.18
6.43
Current year
5.93
Extreme 5.93
6.43
1 year
5.64
Extreme 5.64
6.43
3 years
5.22
Extreme 5.22
7.34
5 years
4.55
Extreme 4.55
7.34
10 years
4.11
Extreme 4.11
7.34
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 23-09-30
Investor Relations Contact - -
Corporate Officer/Principal 58 21-04-30
Members of the board TitleAgeSince
Director/Board Member 67 12-01-23
Chairman 67 11-03-29
Director/Board Member 64 20-12-31
More insiders
Date Price Change Volume
24-05-24 6.27 +0.32% 4,790,900
24-05-23 6.25 -0.32% 5,266,900
24-05-21 6.27 -0.63% 7,147,200
24-05-20 6.31 +0.64% 5,498,800

End-of-day quote BURSA MALAYSIA, May 23, 2024

More quotes
IHH Healthcare Berhad is a Malaysia-based integrated healthcare provider. The Company's segments include Hospital and Healthcare, IMU Health, Labs, PLife REIT and Others. It operates its Hospital and Healthcare segment in Singapore, Malaysia, India, Greater China, Turkey and Europe and Southeast Asia. The IMU Health segment is engaged in providing educational services. The Labs segment provides diagnostic laboratory services. The PLife REIT segment is a real estate investment trust. Through its portfolio of brands, such as Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai and Parkway, the Company offers its patients comprehensive and personalized care ranging from primary to quaternary, and even ancillary services such as laboratory, diagnostics, imaging, and rehabilitation. It provides day-to-day healthcare services through outpatient treatment, routine check-ups, and vaccinations. Its secondary care comprises specialist consultation, local surgeries, and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
6.27 MYR
Average target price
7.13 MYR
Spread / Average Target
+13.72%
Consensus